Rationale: Usual interstitial pneumonia (UIP) is characterized by extracellular matrix deposition and the development of pulmonary fibrosis. Fibroblastic foci found in the lung are believed to represent an early stage in the evolution of this disease. Objectives: To compare gene expression profiles in different components of lung tissue (fibroblastic foci, adjacent epithelium, and areas of type 2 pneumocyte hyperplasia) from patients with UIP, and contrast these profiles to distal, uninvolved (control) alveolar tissue from patients undergoing lung resection for cancer. Methods: Lung resection tissue (UIP, n ϭ 11; controls, n ϭ 11) was snap-frozen for subsequent laser capture microdissection, followed by mRNA extraction, linear amplification, and quantitative realtime polymerase chain reaction. 
of fibrogenic cytokines (7, 8) , providing critical signals to induce fibroblasts to migrate, proliferate, and develop a profibrotic phenotype (6) . Without restoration of the alveolar epithelium, there is continuous invasion of fibroblasts and myofibroblasts, and excessive matrix protein deposition, with resulting intraalveolar fibrosis and loss of gas exchange surface area (6) .
Fibroblastic foci are independent predictors of lung function and mortality in IPF (9) , and are believed to represent early, active areas of aberrant wound repair (1, 10) . The fibroblasts and adjacent epithelial cells appear to actively proliferate (11) , and can be considered epithelial-mesenchymal trophic units (12) . Complex interactions between these cells likely drive the progressive fibrotic process, and understanding this epithelialmesenchymal cross-talk, and specifically which cytokines and growth factors are involved, is vital to our understanding of the pathology of IPF.
Mediators believed to be important in IPF include transforming growth factor (TGF)-␤1, as well as connective tissue growth factor (CTGF), matrix metalloproteases (MMPs) and their inhibitors (tissue inhibitors of MMPs [TIMPs]), and osteopontin. TGF-␤1 is a key growth factor in the initiation of fibrosis (13) , and increased expression of TGF-␤1 mRNA and peptide have been demonstrated in IPF (7, 14) . CTGF is directly induced by TGF-␤1 and, in turn, may be essential for the induction of collagen synthesis by TGF-␤ (15) . An imbalance between the synthesis and degradation of extracellular matrix is central to the progressive fibrosis seen in IPF, and there is evidence that there is a relationship with dysregulation of MMPs and TIMPs (6, 11, (16) (17) (18) . Osteopontin up-regulates MMP-2 synthesis (19, 20) and promotes fibroblast proliferation and migration (21) , whereas osteopontin protein and mRNA expression are upregulated in bleomycin-induced lung injury in mice and in UIP (18, 20, 22, 23) .
The objective of this study was to examine gene expression within specific cell compartments in lung tissue from patients with IPF-namely, the fibroblastic foci, adjacent epithelium, and the hyperplastic type 2 pneumocytes-and compare it with that in alveolar walls from control lungs. Some of the results of this study have been previously reported in the form of an abstract (24) .
METHODS

Subjects
The study was approved by the local research ethics committee, and written consent was obtained from all participants. Patients undergoing diagnostic open lung biopsy for suspected IPF on the basis of their clinical and radiologic presentation were invited to participate in the study. Patients with IPF fulfilled the diagnostic criteria of the 2002 American Thoracic Society/European Respiratory Society consensus report (2) , and the morphologic diagnosis was based on typical microscopic findings of UIP (1) . Histologic assessment confirmed the diagnosis of UIP in 11 patients (10 males; mean age [Ϯ SD] ϭ 62 [9.5] yr), and these were included in this study. Tissue samples from 11 patients undergoing resection for lung cancer were included as comparison controls (7 males; mean age [Ϯ SD] ϭ 65 [10.4] yr), with the tissue being sampled in areas distant from the tumor.
Handling of Lung Tissue and Laser Capture Microdissection
Details are provided in the online supplement.
Gene Expression in Microdissected Tissue
Extraction of RNA from microdissected tissue was performed as previously described (25) and as described in the online supplement.
Immunohistochemistry
Immunohistochemistry was performed on paraffin-processed tissue to detect TGF-␤1, MMP-7, osteopontin, TIMP-1, and ␣-smooth muscle actin (␣-SMA), as described in the online supplement.
Statistical Analysis
Data were analyzed using SPSS version 11.0.0 (SPSS, Inc., Chicago, IL). Reported values are expressed as mean and SEM unless described as otherwise. Normality and variance assumptions were tested for all variables. The gene expression data were nonparametric and were, therefore, logarithmically transformed for analysis. Comparisons between the different tissue samples with respect to gene expression were performed by one-way analysis of variance. Post hoc multiple comparison testing was performed using Bonferroni's test to assess for significant effects. All comparisons were two-tailed, and p values less than 0.05 were considered to be significant. regulated in the fibroblastic foci (p ϭ 0.01) compared with controls. There was decreased expression of MMP-7 in the fibroblastic foci compared with the adjacent epithelium (p ϭ 0.04).
RESULTS
Gene Expression of
Gene Expression of Osteopontin Was Up-regulated within Epithelium Adjacent to Fibroblastic Foci
Compared with control alveoli, gene expression of osteopontin was up-regulated in the epithelium adjacent to fibroblastic foci (p ϭ 0.03), whereas enhanced expression showed a trend to significance in the hyperplastic type 2 pneumocytes (p ϭ 0.08) and the fibroblastic foci (p ϭ 0.08; Figure 1 ). Gene expression of TGF-␤1 and TGF-␤2 was not significantly elevated in any of the selected tissues from patients with IPF, although there was a trend to increased expression in the epithelium adjacent to fibroblastic foci compared with control alveoli (p ϭ 0.09, p ϭ 0.07), respectively ( Figure 2 ). There was also a trend to increased gene expression of CTGF within the fibroblastic foci compared with the adjacent epithelium (p ϭ 0.08).
Gene Expression of ␣-SMA in Fibroblastic Foci and Smooth Muscle
To validate the methodology, epithelial and mesenchymal tissues were examined for their expression of ␣-SMA and smooth muscle myosin gene expression ( Figure 3 ). The levels of gene expression of ␣-SMA within bronchial smooth muscle were significantly increased compared with all epithelial tissues (bronchial epithelium, p ϭ 0.02; hyperplastic type 2 pneumocytes, p Ͻ 0.001; epithelium adjacent to fibroblastic foci, p Ͻ 0.001), and were also increased with a trend to significance when compared with fibroblastic foci (p ϭ 0.08). The metaplastic smooth muscle within areas of chronic fibrosis also showed increased levels of ␣-SMA mRNA compared with bronchial epithelium (p ϭ 0.001), metaplastic epithelium (p ϭ 0.001), and epithelium adjacent to fibroblastic foci (p ϭ 0.003). In addition, ␣-SMA expression was up-regulated in fibroblastic foci compared with adjacent epithelium (p ϭ 0.04) and to hyperplastic type 2 pneumocytes (p ϭ 0.01).
Gene Expression of Smooth Muscle Myosin Was Up-regulated only within Bronchial Smooth Muscle
The levels of gene expression of smooth muscle myosin were significantly increased in the bronchial smooth muscle compared with all the other tissues; bronchial epithelium (p ϭ 0.04), hyperplastic type 2 pneumocytes (p ϭ 0.04), epithelium overlying fibroblastic foci (p ϭ 0.04), fibroblastic foci (p ϭ 0.01), and areas of smooth muscle metaplasia (p ϭ 0.02; Figure 3 ).
Gene Expression of Surfactant Protein C by Alveoli, Hyperplastic Type 2 Pneumocytes, and Epithelium Adjacent to Fibroblastic Foci
Surfactant protein C expression in hyperplastic type 2 pneumocytes was not significantly different from that in alveolar walls (controls), although there was a trend to increased gene expression compared with the epithelium adjacent to fibroblastic foci (p ϭ 0.09). The level of expression in hyperplastic type 2 pneumocytes was significantly higher than that in bronchial epithelium (p ϭ 0.03), fibroblastic foci (0.01), and bronchial smooth muscle (0.01; Figure 4 ).
No Significant Differences in Gene Expression Were Detected when Mixtures of Tissues Were Examined
When gene expression of TGF-␤1, MMP-7, and TIMP-1 was analyzed from whole tissue sections (multiple tissue types), there was no significant difference between the control or UIP tissues ( Figure 5 ).
Protein Expression within the Hyperplastic Type 2 Pneumocytes and Fibroblastic Foci Correlated with Gene Expression
TGF-␤1 protein was present within hyperplastic type 2 pneumocytes and in the epithelium overlying the fibroblastic foci, but not in the fibroblastic foci ( Figures 6A and 6B) . Similarly, MMP-7, osteopontin, and TIMP-1 protein were present within hyperplastic type 2 pneumocytes, the epithelium overlying the fibroblastic foci, and within myofibroblasts contained in the fibroblastic foci ( Figures 6C-6G ). Staining for ␣-SMA protein was strongly positive within the fibroblastic foci ( Figure 6H ), as well as in airway and vascular smooth muscle and in metaplastic smooth muscle present in areas of fibrosis. Normal alveolar walls were negative for MMP-7, but showed scattered, weak staining for TGF-␤1, osteopontin, and TIMP-1, as did airway epithelium.
DISCUSSION
This is the first study to report on cell-specific gene expression in UIP in a quantitative manner. We demonstrated significant upregulation of gene expression within fibroblastic foci of TIMP-1, MMP-2, and MMP-9, with a trend to significance of MMP-7 and osteopontin compared with control alveoli (Figure 1 ). The epithelium adjacent to the fibroblastic foci and the hyperplastic type 2 pneumocytes also showed significant up-regulation of MMP-9 and MMP-7 compared with control alveoli; osteopontin gene expression was significantly up-regulated in the epithelium adjacent to the fibroblastic foci compared with control alveoli. Although MMP-7 expression was significantly increased in the fibroblastic foci compared with control alveoli, it was significantly less than within the epithelium overlying the fibroblastic foci. However, there was increased TIMP-1 and MMP-2 mRNA in the fibroblastic foci compared with the overlying epithelium ( Figure 1 ). We were unable to detect significant upregulation of TGF-␤1, TGF-␤2, or CTGF gene expression in individual cell types or whole UIP tissue (Figure 2) .
To further validate our methodologic approach, we measured the expression of genes specific to certain cell types-namely, ␣-SMA and smooth muscle myosin (both specific for smooth muscle) and surfactant protein C (specific for type 2 pneumocytes)-and confirmed these genes to be present in the relevant cell types (Figures 3 and 4) . We also performed immunohistochemistry to detect immunoreactive protein for TGF-␤1, MMP-7, osteopontin, TIMP-1, and ␣-SMA. These results correlated with the gene expression data (Figure 6 ), thus providing additional validation of those data.
MMPs are bound to cell surfaces, and because their substrate specificity and activity is dictated by the cell expressing them (26) (27) (28) , it is relevant to distinguish their expression by different cell types. Our observed dysregulation of MMP and TIMP-1 gene expression is in keeping with previous studies in experimental fibrosis (29, 30) and UIP (11, 31) , in which a nondegrading extracellular matrix environment is the dominant feature. Despite this, lung biopsy homogenates in UIP have failed to demonstrate up-regulated TIMP gene expression (18, 22) . This failure may be due to the signal from the fibroblastic foci being masked by those from the rest of the lung, and, indeed, we found no significant difference in TIMP-1 gene expression when we analyzed tissue consisting of multiple cell populations ( Figure 5 ). In addition to its inhibitory effects on MMPs, TIMP-1 inhibits fibroblast and myofibroblast apoptosis (32) (33) (34) (35) (36) , and also directly promotes fibroblast growth (37) (38) (39) (40) . The observed up-regulation of TIMP-1 gene expression and presence of the protein in myofibroblasts in fibroblastic foci suggests that TIMP-1 mediates persistence of myofibroblastic differentiation in these foci, even when the overlying epithelium has been lost.
Previous studies demonstrated up-regulated expression of MMP-2 and MMP-9 mRNA in UIP lung homogenates (18, 22) , and MMP-2 and MMP-9 protein presence in myofibroblasts and areas of denuded alveolar basement membrane in UIP (11, 41) . Aside from the effect of MMPs in enhancing extracellular matrix turnover and promoting tissue remodeling, the expression of these gelatinases in myofibroblasts may facilitate their migration through epithelial basement membrane and aid in invasion of the alveoli (11, 31) . MMP-2 and MMP-9 have been shown to play a role in smooth muscle cell migration after injury (42, 43) , with MMP-9 also affecting smooth muscle proliferation (42) and collagen assembly (44) . MMP-2 can activate MMP-9 (45), and both MMP-2 and MMP-9 can activate TGF-␤ (46, 47). Paradoxically, both MMP-2 and MMP-9 can also up-regulate expression of TIMP-1, thereby preventing apoptosis of myofibroblasts. In addition, increased expression of MMP-2 within the fibroblastic foci may stimulate proliferation of fibroblasts within these same foci (48) . MMPs also have effects on the release of other profibrotic factors, such as insulin-like growth factor and tumor necrosis factor-␣ (47, 49). Although most MMPs promote epithelial repair (50), MMP-9 is unique in that it inhibits cell replication in the migrating epithelial sheet (51), and patients with rapid progression may reflect excess MMP-9 activity (52).
Our observation that MMP-7 gene expression is up-regulated in hyperplastic type 2 pneumocytes and epithelium adjacent to fibroblastic foci is in keeping with other studies, which have detected MMP-7 protein expression within alveolar pneumocytes, the interstitium, and fibroblastic foci in UIP (17, 18) . MMP-7 increases the secretion and activation of pro-MMP-2 and pro-MMP-9 (53). Increased local procoagulant activity, attributed to the alveolar epithelial cells, has been observed in IPF (6) , and MMP-7 and MMP-9 are able to rapidly cleave tissue factor pathway inhibitor, an inhibitor of tissue factor-induced coagulation (54) . MMP-7 may also be involved in the release of the profibrotic cytokine tumor necrosis factor-␣ (55, 56). After epithelial injury, MMP-7 causes shedding of epithelial cadherin (E-cadherin), an important mediator of epithelial cell adhesion, and, in IPF, there is persistent shedding of E-cadherin with consequent failure of epithelial repair (57) . There is also evidence of aberrant activation of the Wnt pathway in hyperplastic type 2 pneumocytes and within the fibroblastic foci in UIP (58), which could provide autocrine survival signals to the fibroblasts/ myofibroblasts within the fibroblastic foci (59) (60) (61) . MMP-7 is itself induced by the Wnt/␤-catenin signaling pathway (62) , and may, thereby, initiate a positive feedback loop for its own gene expression in injured epithelium (60) .
Microarray studies have shown significant interaction between osteopontin and MMP-7 (63), and, in UIP, osteopontin protein has been demonstrated in alveolar epithelium and hyper- plastic type 2 pneumocytes, but not within fibroblastic foci (23) . Although osteopontin has previously been shown to be a TGF-␤1 response gene (64) , it may also function upstream of TGF-␤1 by regulating its activation (22, 23, 65) , and it can also activate MMP-2 (66). When treated with bleomycin, osteopontindeficient mice express less MMP-2 and active TGF-␤1 (23), and osteopontin may play an important amplifying or initiating role in up-regulating MMP-7 in epithelial cells and TIMP-1 in fibroblasts (63) . In our study, osteopontin gene expression was upregulated within fibroblastic foci, which correlated with protein expression ( Figure 6E) .
Our results support the hypothesis that myofibroblasts within the fibroblastic foci are able to penetrate the overlying epithelial basement membrane through their ability to produce MMP-2 and MMP-9. Attempts to re-epithelialize the fibroblastic foci may be hindered by high levels of MMP-7 and MMP-9 secreted by the epithelial cells themselves and by the myofibroblasts within the fibroblastic foci, which results in persistent epithelial disruption. The "injured" epithelium chronically produces MMP-7, MMP-9, and osteopontin, and, together with TIMP-1 production by the fibroblastic foci, results in a persistent imbalance in collagen synthesis and degradation, with progressive enlargement of the fibroblastic foci.
Despite TGF-␤1 being strongly associated with UIP (67, 68), and TGF-␤ mRNA and protein having been found at increased levels within the sites of extracellular matrix accumulation (69), we did not find a significant up-regulation of TGF-␤1 or TGF-␤2 within the fibroblastic foci in our study. TGF-␤1 protein was demonstrated to be present within hyperplastic type 2 pneumocytes and the epithelium overlying the fibroblastic foci, but not within the fibroblastic foci itself (Figures 6A and 6B) , which supports the gene expression findings. Similarly, a previous study showed that immunoreactive TGF-␤1 was present in alveolar macrophages and epithelial cells of patients with IPF, but was absent in fibroblasts in the subepithelial regions of honeycomb cysts (70) . In addition, a study of UIP using in situ hybridization demonstrated that TGF-␤1 mRNA was present in macrophages adjacent to fibroblastic foci, but that the foci themselves showed no signal for TGF-␤1 mRNA (14) . Global gene profiling of lung treated with bleomycin in experimental fibrosis has also failed to detect a significant increase in TGF-␤ mRNA, despite marked up-regulation of numerous TGF-␤1-inducible genes (22) . The lower respiratory tract usually contains high levels of latent TGF-␤1 (71), although macrophages, rather than epithelium, appear to be the primary source of TGF-␤1 (72) . Although structural cells in UIP may not be the source of increased TGF-␤1, they may activate matrix-associated TGF-␤1 protein through their production of MMP-2, MMP-9, and osteopontin, resulting in persistent expression of genes relating to tissue fibrosis (47, 73) . Thus, our findings do not exclude a role for TGF-␤1 in initiating myofibroblast development within fibroblastic foci, and these myofibroblasts may be more responsive to growth factors such as TGF-␤1 and CTGF (74) .
We did not observe a significant difference in CTGF gene expression between fibroblastic foci and control alveoli, although there was a trend toward significantly increased mRNA within the fibroblastic foci compared with the adjacent epithelium. Although a previous study has shown increased expression of CTGF mRNA and protein in alveolar type 2 cells and interstitial fibroblasts in UIP (75), we have previously found only transient fibrosis on adenovirus vector transfer of CTGF to the rodent lung (76) . Our finding of significant up-regulation of TIMP-1, but not CTGF, within the fibroblastic foci suggests decreased degradation of collagen, rather than enhanced synthesis, as the mechanism for the fibrosis seen in UIP.
As expected, we found that the smooth muscle cell genes, ␣-SMA and smooth muscle myosin, were present at a high level within bronchial smooth muscle, and ␣-SMA also showed significant up-regulation in fibroblastic foci and the areas of metaplastic smooth muscle (Figure 3) . We did not find up-regulation of ␣-SMA gene or protein expression in the epithelium adjacent to the fibroblastic foci, despite a recent study suggesting epithelialmesenchymal transition in IPF (77) . Similarly, surfactant protein C, a gene specific to type 2 pneumocytes, was present at a high level in the control alveoli and the hyperplastic type 2 pneumocytes only (Figure 4) . Mutations in the surfactant protein C gene have been linked to familial forms of pulmonary fibrosis (78) , and it has recently been shown that surfactant protein C-deficient mice had increased fibrosis with an associated delay in fibrosis resolution in a bleomycin-induced pulmonary fibrosis model (79) . Interestingly, in our study, there was a trend toward a significant reduction in surfactant protein C gene expression in the epithelium adjacent to the fibroblastic foci compared with the hyperplastic type 2 pneumocytes. This may reflect a more severe injury in these cells.
When mRNA was extracted from multiple cell types present in a total tissue section, the differences in gene regulation seen between the UIP and control samples were lost ( Figure 5 ), emphasizing the unique information gained from this methodology. Laser capture microdissection with quantitative RT-PCR has the advantages over in situ hybridization of allowing the examination of several different genes simultaneously and providing a more sensitive, quantitative measurement. Alveoli distant from tumor-free areas of lung resected for lung cancer were chosen as the control in this study, as UIP affects the distal pulmonary acinus and there is evidence that alveolar pneumocytes are the cell type initiating the disease (80) . Although gene expression studies cannot provide information on post-translational modifications of proteins, this study demonstrates the validity and usefulness of being able to examine gene expression in specific cell populations in the lung in UIP.
Useful as animal models of pulmonary fibrosis are, they show significant differences in pathogenesis and outcome when compared with IPF (81), and, therefore, studies on human subjects with IPF are important. Gene microarray studies in IPF have yielded valuable information (17, 18) , but are limited by their inability to determine which cells are responsible for specific gene overexpression. Changes in gene expression may merely reflect changes in cellular composition, and signals from relatively small areas, such as fibroblastic foci, may be masked by quantitatively stronger signals from other tissues. Because many genes are multifunctional, it is important to assess their expression in the correct tissue context. By examining gene expression within fibroblastic foci, the adjacent epithelium, and in areas of hyperplastic type 2 pneumocytes, we believe that we were able to examine early events in this chronic but temporally heterogeneous disease. The similarities in the gene expression profile between the hyperplastic type 2 pneumocytes and the epithelium overlying the fibroblastic foci suggest that type 2 cells may represent injured epithelium, which subsequently initiates the fibroblastic response, rather than constituting a nonspecific reactive process. Type 2 pneumocytes have direct contact with underlying fibroblasts (82) , and it has been suggested that an underlying defect in the type 2 pneumocyte may be responsible for initiation of UIP (6, 83, 84) . Our findings of up-regulated gene expression of MMP-7, -9, and osteopontin within the epithelium adjacent to fibroblastic foci may represent a mechanism of persistence, or even initiation, of these foci. Osteopontin and MMP-7 may be key molecules in this regard, as they are upregulated in both the epithelium adjacent to the fibroblastic foci and in the hyperplastic type 2 epithelium.
Our findings of significantly up-regulated TIMP-1 expression within the fibroblastic foci suggest that decreased collagen breakdown, due to the presence of a nondegrading environment (11) , is a more important pathogenetic mechanism than excessive collagen synthesis in the evolution of this disease. As such, new therapies may be better targeted at reversing the inhibition of collagen degradation rather than preventing the synthesis of new collagen.
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